Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

OBJECTIVE: Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes auto...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes Care
Glavni autori: Demeester, Simke, Keymeulen, Bart, Kaufman, Leonard, Van Dalem, Annelien, Balti, Eric V., Van de Velde, Ursule, Goubert, Patrick, Verhaeghen, Katrijn, Davidson, Howard W., Wenzlau, Janet M., Weets, Ilse, Pipeleers, Daniel G., Gorus, Frans K.
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2015
Teme:
Emerging Technologies and Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4370324/
https://ncbi.nlm.nih.gov/pubmed/25583753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc14-1575
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items